Evidence map›Paper›PMID 40800773›Full record

ArticleImaging neuroscience (Cambridge, Mass.)2025

Dopamine alters functional gradients in Parkinson's disease.

Isabella F Orlando, Joshua B Tan, Natasha L Taylor, Vicente Medel, Gabriel Wainstein, Simon J G Lewis, James M Shine, Claire O'Callaghan

Abstract read
In one paragraph

Article in Imaging neuroscience (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Isabella F OrlandoBrain and Mind Centre and School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.ORCID https://orcid.org/0009-0001-4515-3479
Joshua B TanBrain and Mind Centre and School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Natasha L TaylorBrain and Mind Centre and School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Vicente MedelLatin American Brain Health Institute (BrainLat), Universidad Adolfo Ibáñez, Santiago, Chile.
Gabriel WainsteinBrain and Mind Centre and School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Simon J G LewisMacquarie University Centre for Parkinson's Disease Research and Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.
James M ShineBrain and Mind Centre and School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Claire O'CallaghanBrain and Mind Centre and School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.ORCID https://orcid.org/0000-0001-5698-6364

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuromodulators regulate large-scale brain network topology to support adaptive behaviour. Disease models offer a unique window into how neuromodulatory systems impact large-scale brain network organisation. Here, we take advantage of Parkinson's disease-with its profound dopaminergic loss and pro-dopaminergic treatment strategies-to inform how dopamine may influence large-scale brain organisation. In 27 people with Parkinson's disease, resting-state scans were obtained on their regular dopamine medication and following overnight withdrawal of medication. Nineteen matched controls provided normative data. Gradients of brain organisation were examined using dimensionality reduction techniques. For single gradients, when individuals were on their dopamine medication, we observed a shift in higher-order networks towards somatomotor anchors. When interrogated in the multi-dimensional gradient space, we found that dopamine medication enhanced separation between functionally discrete sensory and higher-order networks. This increase in dispersion was dependent on an individual's dopamine dose level, and increased dispersion was more apparent in regions enriched with dopamine receptor (DRD2) gene expression. Together, these findings substantiate a role for dopamine in modulating large-scale functional brain organisation. Our findings further confirm that medication targeting the dopamine system may achieve its benefit by restoring aspects of network topology, and suggest new hypotheses about how dopamine medication is influencing large-scale functional brain organisation in Parkinson's disease.

Indexed as

dopaminefunctional gradientsParkinson’s diseasereceptor expressionresting-state fMRI

Identifiers

PMID40800773
PMCPMC12319910

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.